Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
DELCO Today on MSN21 小时
Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test
The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive ...
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Why Hims & Hers Stock Just Collapsed
Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
Is Pfizer Inc. (PFE) the Best Weight Loss Drug Stock to Buy According to Analysts?
We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...
Novo Nordisk stock sinks on weight loss drug trial letdown
Novo Nordisk (NVO) shares stumble after the results of the drugmaker's weight loss drug trial showed that patients using the drug dropped only around 15% of their weight, compared to the 25% that was ...
Yahoo Finance6 天
Surprising decision sends weight-loss drug stock reeling
Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues ... up competition involving weight-loss drugs. The Food and Drug Administration two years ...